BMS' Opdivo Blasts Through NICE
This article was originally published in Scrip
Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) has won a recommendation from NICE, the health technology appraisal institute for England and Wales, for use on the NHS as a monotherapy for melanoma. The drug went straight to the final stages of the appraisal process and will compete against Merck & Co's own PD-1 inhibitor Keytruda (pembrolizumab). Meanwhile, research and patient organizations have expressed relief that NICE has okayed another "exciting" new immunotherapy for cancer.